Detalles de la búsqueda
1.
Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
J Thromb Thrombolysis
; 51(2): 349-358, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32588288
2.
Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization.
Ann Vasc Surg
; 75: 217-226, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33819600
3.
Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin.
J Stroke Cerebrovasc Dis
; 30(5): 105715, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33743312
4.
Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin.
Stroke
; 51(2): 549-555, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31888412
5.
Assessing stroke severity using electronic health record data: a machine learning approach.
BMC Med Inform Decis Mak
; 20(1): 8, 2020 01 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31914991
6.
Duration of anticoagulant therapy and VTE recurrence in patients with cancer.
Support Care Cancer
; 27(10): 3833-3840, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30734088
7.
Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
Am J Hematol
; 93(5): 664-671, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29396864
8.
The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation.
Am J Hematol
; 94(2): E58-E61, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30474161
9.
An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution".
Am J Hematol
; 93(9): E225-E227, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29905381
10.
Antiplatelet treatment patterns and outcomes of secondary stroke prevention in the United States.
Heliyon
; 9(2): e13579, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36852046
11.
Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US.
Heliyon
; 9(2): e13258, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36846680
12.
Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States.
Clin Appl Thromb Hemost
; 28: 10760296221120421, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35996822
13.
Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records.
TH Open
; 6(4): e408-e420, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36452205
14.
Healthcare costs before and after stroke in patients with non-valvular atrial fibrillation who initiated treatment with rivaroxaban or warfarin.
J Med Econ
; 24(1): 212-217, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33499689
15.
Healthcare costs of patients with cancer stratified by Khorana score risk levels.
J Med Econ
; 24(1): 866-873, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34181497
16.
Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization.
J Med Econ
; 24(1): 402-409, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33634723
17.
Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States.
Am Health Drug Benefits
; 13(5): 184-190, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33343818
18.
Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting.
Drugs Aging
; 37(4): 281-289, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32147804
19.
Healthcare resource utilization and costs among nonvalvular atrial fibrillation patients initiating rivaroxaban or warfarin in skilled nursing facilities: a retrospective cohort study.
Curr Med Res Opin
; 36(4): 529-536, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31858841
20.
Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
J Med Econ
; 23(11): 1365-1374, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32897766